University of North Carolina, Chapel Hill
To determine if oral ketorolac given at different timepoints prior to intrauterine device (IUD) insertion influences pain experienced during this procedure.
This is a single-site prospective interventional randomized controlled trial to examine the timing of administration of ketorolac for IUD pain control. 108 patients will be recruited to the study and they will be randomized into three study arms in a 1:1:1 ratio. Information including demographics, medical history, and obstetric history will be collected during enrollment. Patients will arrive 3 hours prior to their IUD appointment. Study group "K2" will receive ketorolac 20mg per os (PO) at 2 hours prior to IUD insertion, then they will receive a placebo pill at 1 hour prior to IUD insertion.…
Inclusion Criteria: * 18 years or older * Able to consent * Desires IUD insertion Exclusion Criteria: * IUD placement under sedation or oral anxiolytic * IUD replacement (removal with insertion) * Daily narcotic or NSAID use * Contraindications to IUD placement * Current: pregnancy, genital/pelvic infection * Lifetime history: uterine anomaly, pelvic inflammatory disease, allergy to levonorgestrel or copper * Contraindications to ketorolac * Current: weight under 50 kilograms * Lifetime history: allergy to NSAIDs, liver disease, renal disease, peptic ulcer disease, cerebrovascular bleeding,…
The experimental condition to be examined by this study is the timing of administration of ketorolac prior to IUD insertion. Ketorolac 20mg PO has proven beneficial at certain timepoints during IUD insertion in prior studies, but pharmacokinetics indicate that it could require more time until peak analgesia.
Placebo will be used to control the timing of administration and be used to compare ketorolac to baseline standard pain control regimens
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.